BMS-986504 for Peripheral Nerve Sheath Tumor

This trial explores a new treatment called BMS-986504, an experimental drug, for Malignant Peripheral Nerve Sheath Tumor (MPNST). The researchers aim to determine if this medicine outperforms current options, particularly in patients with a specific genetic change known as MTAP loss. This genetic change might enhance the treatment's effectiveness. Individuals diagnosed with MPNST, whose tumors cannot be surgically removed, and who have the MTAP loss may be suitable candidates for the trial. As a Phase 1, Phase 2 trial, this research focuses on understanding the treatment's effects in people and measuring its effectiveness in an initial, smaller group.

You may need to stop taking certain medications before joining the trial. Specifically, you cannot use any strong inhibitors or inducers of CYP3A4, P-gp, or proton pump inhibitors unless they can be switched to an alternative treatment before starting the study.

Research has shown that BMS-986504 is usually well-tolerated by patients. In earlier studies, most side effects were mild and not serious, with only about 14% of participants experiencing more serious side effects. Researchers are testing this treatment for its ability to target MPNST, particularly when surgery isn't an option. Early results are promising, suggesting it might be a safe option for many people.¹²³⁴⁵

Unlike the standard treatments for peripheral nerve sheath tumors, which often involve surgery, radiation, and chemotherapy, BMS-986504 represents a new approach by potentially targeting specific molecular pathways involved in tumor growth. Researchers are excited about BMS-986504 because it could offer a more targeted treatment option, minimizing damage to surrounding healthy tissues and potentially leading to fewer side effects. This drug is also being tested for its ability to halt disease progression more effectively than existing therapies, which could significantly improve patient outcomes.

Research suggests that the drug BMS-986504, which participants in this trial will receive, might help treat Malignant Peripheral Nerve Sheath Tumor (MPNST), particularly in tumors lacking the MTAP gene. BMS-986504 blocks an enzyme called PRMT5, which aids cancer cell growth. In other cancers, such as non-small cell lung cancer (NSCLC), about 29% of patients experienced tumor shrinkage with BMS-986504. Notably, this drug has little effect on tumors without the MTAP gene change, indicating it specifically targets tumors with this genetic difference. Overall, this offers hope for its potential effectiveness in treating MPNST with MTAP loss.¹²³⁶⁷